EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first‐line options for HER2‐positive relapsed or metastatic breast cancer

Xiuwen Guan, Fei Ma iD, Binghe Xu

Cancer Innovation · 2022-08 · 1 (2) · 119-123

DOI: 10.1002/cai2.21 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Innovation, online erschienen am 14.07.2022. Verfasst von Xiuwen Guan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Scienc…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

HER2‐targeted therapybreast cancertyrosine kinase inhibitor

Autor:innen und Institutionen

  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
  • Department of Medical Oncology and Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing…

ORCID-Profile: Fei Ma

Zitieren

APA

Guan, X., Ma, F., & Xu, B. (2022). Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first‐line options for HER2‐positive relapsed or metastatic breast cancer. Cancer Innovation, 1(2), 119-123. https://doi.org/10.1002/cai2.21

Vancouver

Guan X, Ma F, Xu B. Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first‐line options for HER2‐positive relapsed or metastatic breast cancer. Cancer Innovation. 2022;1(2):119-123. doi:10.1002/cai2.21

BibTeX
@article{Guan2022,
  author = {Guan, Xiuwen and Ma, Fei and Xu, Binghe},
  title = {Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first‐line options for HER2‐positive relapsed or metastatic breast cancer},
  journal = {Cancer Innovation},
  year = {2022},
  volume = {1},
  number = {2},
  pages = {119--123},
  doi = {10.1002/cai2.21}
}
Kostenlos starten →